Loading...
XHKG
2196
Market cap8.51bUSD
Apr 03, Last price  
15.70HKD
1D
0.00%
1Q
14.77%
Jan 2017
-33.89%
Name

Shanghai Fosun Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
P/E
14.97
P/S
0.86
EPS
0.98
Div Yield, %
1.91%
Shrs. gr., 5y
1.16%
Rev. gr., 5y
10.69%
Revenues
41.40b
-5.81%
2,425,435,9182,988,526,8243,102,002,4043,693,301,6783,773,234,2203,872,256,3264,555,421,6866,485,540,8007,340,782,7219,996,409,00912,025,532,04512,608,648,31414,628,820,44318,533,555,41824,918,273,56128,585,152,03330,306,981,26439,005,086,60243,951,546,89541,399,539,588
Net income
2.39b
-36.04%
215,333,391159,030,715259,157,973625,781,242690,856,5412,498,201,836863,653,9061,165,607,6291,563,916,4412,027,057,7362,112,869,4672,460,093,5832,805,837,0713,124,499,5492,707,923,4183,321,617,5663,662,812,9374,728,710,5273,730,804,5822,386,265,813
CFO
4.36b
+3.45%
205,100,591188,346,350184,914,259131,477,131233,041,247261,867,525203,362,919316,649,971665,517,0201,011,633,3741,200,214,1911,621,027,8752,110,039,2652,580,225,7752,950,105,2133,222,412,5712,579,774,3493,948,747,0094,217,570,8924,363,275,634
Dividend
Jul 26, 20240.3 HKD/sh

Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
URL
https://www.fosunpharma.com/
IPO date
Aug 07, 1998
Employees
38,591
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
41,399,540
-5.81%
43,951,547
12.68%
Cost of revenue
33,314,223
37,631,021
Unusual Expense (Income)
NOPBT
8,085,317
6,320,525
NOPBT Margin
19.53%
14.38%
Operating Taxes
369,504
626,917
Tax Rate
4.57%
9.92%
NOPAT
7,715,812
5,693,608
Net income
2,386,266
-36.04%
3,730,805
-21.10%
Dividends
(2,455,170)
(1,435,465)
Dividend yield
3.66%
1.56%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
14,728,454
17,402,869
Long-term debt
17,604,102
13,589,854
Deferred revenue
632,433
Other long-term liabilities
7,541,248
2,916,694
Net debt
(8,809,372)
(10,797,642)
Cash flow
Cash from operating activities
4,363,276
4,217,571
CAPEX
(5,336,705)
Cash from investing activities
(4,777,859)
Cash from financing activities
(1,326,740)
4,428,475
FCF
2,287,458
1,848,390
Balance
Cash
15,582,087
17,169,846
Long term investments
25,559,840
24,620,519
Excess cash
39,071,951
39,592,787
Stockholders' equity
36,846,319
38,519,031
Invested Capital
57,594,157
48,456,900
ROIC
14.55%
12.53%
ROCE
8.56%
7.00%
EV
Common stock shares outstanding
2,681,198
2,607,385
Price
25.03
-28.97%
35.24
-27.99%
Market cap
67,110,375
-26.96%
91,884,247
-26.74%
EV
69,232,502
90,613,057
EBITDA
11,203,995
8,656,437
EV/EBITDA
6.18
10.47
Interest
1,324,831
963,807
Interest/NOPBT
16.39%
15.25%